Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer

Han Han; Yuchen Chen; Xiyong Wang

doi:doi:10.11648/j.sd.20241203.15

Research Article |

| Peer-Reviewed

Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer

Han Han, Yuchen Chen, Xiyong Wang^*

Published in Science Discovery (Volume 12, Issue 3)

Received: 14 May 2024 Accepted: 17 June 2024 Published: 19 June 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Small cell lung cancer has high malignant degree, rapid progression and poor prognosis, and has lacked effective treatment strategies for a long time. In the past, the treatment strategy for small cell lung cancer has been dominated by chemotherapy and radiotherapy, and although first-line treatment is highly effective, the vast majority of patients will relapse and become resistant within a year.In recent years, the application and research of immune checkpoint inhibitors in small cell lung cancer have been increasing, bringing new hope for survival of small cell lung cancer patients, multiple clinical trials have demonstrated long-lasting efficacy and clinical activity of programmed death receptor/ligand-1 and cytotoxic T lymphocyte antigen-4 in small cell lung cancer. The main immune checkpoint inhibitors that have been well studied in small cell lung cancer are Nivolumab, Pembrolizumab, Serplulimab, Tislelizumab, Atezolizumab, Durvalumab, Adebrelimab and Ipilimumab. In this paper, the research progress of these drugs is reviewed, and the research progress of the combined application of immune checkpoint inhibitors with chemotherapy, radiotherapy, PARP inhibitors, WEE1 inhibitors, etc. The final results showed that immune checkpoint inhibitors brought survival benefits to patients with small cell lung cancer. However, due to the particularity of this disease, the survival time is still shorter than that of non-small cell lung cancer. It is expected that follow-up studies can further extend the survival time of patients.

Published in	Science Discovery (Volume 12, Issue 3)
DOI	10.11648/j.sd.20241203.15
Page(s)	63-67
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Small Cell Lung Cancer, Immune Checkpoint Inhibitors, Clinical Trial

References

[1]	ROWSHANRAVAN B, HALLIDAY N, SANSOM D M. CTLA-4: a moving target in immunotherapy [J]. Blood, 2018, 131(1): 58-67.
[2]	MADDISON P, NEWSOM-DAVIS J, MILLS K R, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma [J]. Lancet, 1999, 353(9147): 117-8.
[3]	ANTONIA S J, LóPEZ-MARTIN J A, BENDELL J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J]. Lancet Oncol, 2016, 17(7): 883-95.
[4]	SPIGEL D R, VICENTE D, CIULEANU T E, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆) [J]. Ann Oncol, 2021, 32(5): 631-41.
[5]	LEAL T, WANG Y, DOWLATI A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161 [J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 9000-.
[6]	OTT P A, ELEZ E, HIRET S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study [J]. J Clin Oncol, 2017, 35(34): 3823-9.
[7]	CHUNG H C, PIHA-PAUL S A, LOPEZ-MARTIN J, et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies [J]. J Thorac Oncol, 2020, 15(4): 618-27.
[8]	RUDIN C M, AWAD M M, NAVARRO A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study [J]. J Clin Oncol, 2020, 38(21): 2369-79.
[9]	CHENG Y, HAN L, WU L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial [J]. Jama, 2022, 328(12): 1223-32.
[10]	CHENG Y, HAN L, WU L, et al. Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005) [J]. Annals of Oncology, 2022, 33: S1562-S.
[11]	CHENG Y, FAN Y, ZHAO Y, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial [J]. J Thorac Oncol, 2024.
[12]	CHIANG A C, SEQUIST L V D, GILBERT J, et al. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer [J]. Clin Lung Cancer, 2020, 21(5): 455-63.e4.
[13]	HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-7.
[14]	HORN L, MANSFIELD A S, SZCZĘSNA A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J]. N Engl J Med, 2018, 379(23): 2220-9.
[15]	PUJOL J L, GREILLIER L, AUDIGIER-VALETTE C, et al. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial [J]. J Thorac Oncol, 2019, 14(5): 903-13.
[16]	BONDARENKO I, JUAN-VIDAL O, PAJKOS G, et al. Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study [J]. Annals of Oncology, 2018, 29: viii596.
[17]	PAZ-ARES L, DVORKIN M, CHEN Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J]. Lancet, 2019, 394(10212): 1929-39.
[18]	WANG J, ZHOU C, YAO W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2022, 23(6): 739-47.
[19]	RECK M, LUFT A, SZCZESNA A, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer [J]. J Clin Oncol, 2016, 34(31): 3740-8.
[20]	CHAUVIN J M, ZAROUR H M. TIGIT in cancer immunotherapy [J]. J Immunother Cancer, 2020, 8(2).
[21]	QIN S, XU L, YI M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 [J]. Mol Cancer, 2019, 18(1): 155.
[22]	ANDERSON A C. Tim-3, a negative regulator of anti-tumor immunity [J]. Curr Opin Immunol, 2012, 24(2): 213-6.
[23]	HAANEN J B, CERUNDOLO V. NKG2A, a New Kid on the Immune Checkpoint Block [J]. Cell, 2018, 175(7): 1720-2.
[24]	BRAZEL D, OU S I, NAGASAKA M. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno [J]. Lung Cancer (Auckl), 2023, 14: 1-9.
[25]	ARINA A, GUTIONTOV S I, WEICHSELBAUM R R. Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite" [J]. Clin Cancer Res, 2020, 26(12): 2777-82.
[26]	EL CHEDIAK A, SHAMSEDDINE A, BODGI L, et al. Optimizing tumor immune response through combination of radiation and immunotherapy [J]. Med Oncol, 2017, 34(9): 165.
[27]	WELSH J W, HEYMACH J V, CHEN D, et al. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer [J]. J Thorac Oncol, 2020, 15(2): 266-73.
[28]	GHIRINGHELLI F, APETOH L. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy [J]. Expert Rev Clin Immunol, 2014, 10(1): 19-30.
[29]	REITS E A, HODGE J W, HERBERTS C A, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy [J]. J Exp Med, 2006, 203(5): 1259-71.
[30]	WELSH J W, HEYMACH J V, GUO C, et al. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC [J]. J Thorac Oncol, 2020, 15(12): 1919-27.
[31]	STEWART R A, PILIé P G, YAP T A. Development of PARP and Immune-Checkpoint Inhibitor Combinations [J]. Cancer Res, 2018, 78(24): 6717-25.
[32]	SEN T, RODRIGUEZ B L, CHEN L, et al. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer [J]. Cancer Discov, 2019, 9(5): 646-61.
[33]	DO K, DOROSHOW J H, KUMMAR S. Wee1 kinase as a target for cancer therapy [J]. Cell Cycle, 2013, 12(19): 3159-64.
[34]	TANIGUCHI H, CAESER R, CHAVAN S S, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC [J]. Cell Rep, 2022, 39(7): 110814.

Cite This Article

Plain Text BibTeX RIS

APA Style

Han, H., Chen, Y., Wang, X. (2024). Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Science Discovery, 12(3), 63-67. https://doi.org/10.11648/j.sd.20241203.15

Copy | Download

ACS Style

Han, H.; Chen, Y.; Wang, X. Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Sci. Discov. 2024, 12(3), 63-67. doi: 10.11648/j.sd.20241203.15

Copy | Download

AMA Style

Han H, Chen Y, Wang X. Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Sci Discov. 2024;12(3):63-67. doi: 10.11648/j.sd.20241203.15

Copy | Download

@article{10.11648/j.sd.20241203.15,
  author = {Han Han and Yuchen Chen and Xiyong Wang},
  title = {Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
},
  journal = {Science Discovery},
  volume = {12},
  number = {3},
  pages = {63-67},
  doi = {10.11648/j.sd.20241203.15},
  url = {https://doi.org/10.11648/j.sd.20241203.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20241203.15},
  abstract = {Small cell lung cancer has high malignant degree, rapid progression and poor prognosis, and has lacked effective treatment strategies for a long time. In the past, the treatment strategy for small cell lung cancer has been dominated by chemotherapy and radiotherapy, and although first-line treatment is highly effective, the vast majority of patients will relapse and become resistant within a year.In recent years, the application and research of immune checkpoint inhibitors in small cell lung cancer have been increasing, bringing new hope for survival of small cell lung cancer patients, multiple clinical trials have demonstrated long-lasting efficacy and clinical activity of programmed death receptor/ligand-1 and cytotoxic T lymphocyte antigen-4 in small cell lung cancer. The main immune checkpoint inhibitors that have been well studied in small cell lung cancer are Nivolumab, Pembrolizumab, Serplulimab, Tislelizumab, Atezolizumab, Durvalumab, Adebrelimab and Ipilimumab. In this paper, the research progress of these drugs is reviewed, and the research progress of the combined application of immune checkpoint inhibitors with chemotherapy, radiotherapy, PARP inhibitors, WEE1 inhibitors, etc. The final results showed that immune checkpoint inhibitors brought survival benefits to patients with small cell lung cancer. However, due to the particularity of this disease, the survival time is still shorter than that of non-small cell lung cancer. It is expected that follow-up studies can further extend the survival time of patients.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer

AU  - Han Han
AU  - Yuchen Chen
AU  - Xiyong Wang
Y1  - 2024/06/19
PY  - 2024
N1  - https://doi.org/10.11648/j.sd.20241203.15
DO  - 10.11648/j.sd.20241203.15
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 63
EP  - 67
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20241203.15
AB  - Small cell lung cancer has high malignant degree, rapid progression and poor prognosis, and has lacked effective treatment strategies for a long time. In the past, the treatment strategy for small cell lung cancer has been dominated by chemotherapy and radiotherapy, and although first-line treatment is highly effective, the vast majority of patients will relapse and become resistant within a year.In recent years, the application and research of immune checkpoint inhibitors in small cell lung cancer have been increasing, bringing new hope for survival of small cell lung cancer patients, multiple clinical trials have demonstrated long-lasting efficacy and clinical activity of programmed death receptor/ligand-1 and cytotoxic T lymphocyte antigen-4 in small cell lung cancer. The main immune checkpoint inhibitors that have been well studied in small cell lung cancer are Nivolumab, Pembrolizumab, Serplulimab, Tislelizumab, Atezolizumab, Durvalumab, Adebrelimab and Ipilimumab. In this paper, the research progress of these drugs is reviewed, and the research progress of the combined application of immune checkpoint inhibitors with chemotherapy, radiotherapy, PARP inhibitors, WEE1 inhibitors, etc. The final results showed that immune checkpoint inhibitors brought survival benefits to patients with small cell lung cancer. However, due to the particularity of this disease, the survival time is still shorter than that of non-small cell lung cancer. It is expected that follow-up studies can further extend the survival time of patients.

VL  - 12
IS  - 3
ER  -

Copy | Download

Author Information

Han Han

Oncology Department, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou, China

Contact Email
Yuchen Chen

Oncology Department, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou, China

Contact Email
Xiyong Wang

Oncology Department, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou, China

Contact Email

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Han, H., Chen, Y., Wang, X. (2024). Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Science Discovery, 12(3), 63-67. https://doi.org/10.11648/j.sd.20241203.15

Copy | Download

ACS Style

Han, H.; Chen, Y.; Wang, X. Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Sci. Discov. 2024, 12(3), 63-67. doi: 10.11648/j.sd.20241203.15

Copy | Download

AMA Style

Han H, Chen Y, Wang X. Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer. Sci Discov. 2024;12(3):63-67. doi: 10.11648/j.sd.20241203.15

Copy | Download

@article{10.11648/j.sd.20241203.15,
  author = {Han Han and Yuchen Chen and Xiyong Wang},
  title = {Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
},
  journal = {Science Discovery},
  volume = {12},
  number = {3},
  pages = {63-67},
  doi = {10.11648/j.sd.20241203.15},
  url = {https://doi.org/10.11648/j.sd.20241203.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20241203.15},
  abstract = {Small cell lung cancer has high malignant degree, rapid progression and poor prognosis, and has lacked effective treatment strategies for a long time. In the past, the treatment strategy for small cell lung cancer has been dominated by chemotherapy and radiotherapy, and although first-line treatment is highly effective, the vast majority of patients will relapse and become resistant within a year.In recent years, the application and research of immune checkpoint inhibitors in small cell lung cancer have been increasing, bringing new hope for survival of small cell lung cancer patients, multiple clinical trials have demonstrated long-lasting efficacy and clinical activity of programmed death receptor/ligand-1 and cytotoxic T lymphocyte antigen-4 in small cell lung cancer. The main immune checkpoint inhibitors that have been well studied in small cell lung cancer are Nivolumab, Pembrolizumab, Serplulimab, Tislelizumab, Atezolizumab, Durvalumab, Adebrelimab and Ipilimumab. In this paper, the research progress of these drugs is reviewed, and the research progress of the combined application of immune checkpoint inhibitors with chemotherapy, radiotherapy, PARP inhibitors, WEE1 inhibitors, etc. The final results showed that immune checkpoint inhibitors brought survival benefits to patients with small cell lung cancer. However, due to the particularity of this disease, the survival time is still shorter than that of non-small cell lung cancer. It is expected that follow-up studies can further extend the survival time of patients.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer

AU  - Han Han
AU  - Yuchen Chen
AU  - Xiyong Wang
Y1  - 2024/06/19
PY  - 2024
N1  - https://doi.org/10.11648/j.sd.20241203.15
DO  - 10.11648/j.sd.20241203.15
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 63
EP  - 67
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20241203.15
AB  - Small cell lung cancer has high malignant degree, rapid progression and poor prognosis, and has lacked effective treatment strategies for a long time. In the past, the treatment strategy for small cell lung cancer has been dominated by chemotherapy and radiotherapy, and although first-line treatment is highly effective, the vast majority of patients will relapse and become resistant within a year.In recent years, the application and research of immune checkpoint inhibitors in small cell lung cancer have been increasing, bringing new hope for survival of small cell lung cancer patients, multiple clinical trials have demonstrated long-lasting efficacy and clinical activity of programmed death receptor/ligand-1 and cytotoxic T lymphocyte antigen-4 in small cell lung cancer. The main immune checkpoint inhibitors that have been well studied in small cell lung cancer are Nivolumab, Pembrolizumab, Serplulimab, Tislelizumab, Atezolizumab, Durvalumab, Adebrelimab and Ipilimumab. In this paper, the research progress of these drugs is reviewed, and the research progress of the combined application of immune checkpoint inhibitors with chemotherapy, radiotherapy, PARP inhibitors, WEE1 inhibitors, etc. The final results showed that immune checkpoint inhibitors brought survival benefits to patients with small cell lung cancer. However, due to the particularity of this disease, the survival time is still shorter than that of non-small cell lung cancer. It is expected that follow-up studies can further extend the survival time of patients.

VL  - 12
IS  - 3
ER  -

Copy | Download